United Therapeutics Corp. (UTHR)

$ 314.06
   
  • Change Today:
    $3.40
  • 52 Week High: $410.00
  • 52 Week Low: $274.70
  • Currency: US Dollars
  • Shares Issued: 43.56m
  • Volume: 214,853
  • Market Cap: $13,682m
  • RiskGrade: 132
  • Beta: 0.01

GlaxoSmithKline reportedly running the ruler over US rival

By Alexander Bueso

Date: Friday 04 Aug 2017

LONDON (ShareCast) - (ShareCast News) - GlaxoSmithKline may be studying a possible bid for US rival United Therapeutics, The Evening Standard reported citing City sources.
If correct, the London-based outfit would be up against rival suitors such as Gilead Sciences and Novartis.

According to the same sources cited by the Evening Standard, United was likely to attract a valuation of up to $200 a share, which would translate into a price tag of approximately $8.7bn.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

UTHR Market Data

Currency US Dollars
Share Price $ 314.06
Change Today $ 3.40
% Change 1.10 %
52 Week High $410.00
52 Week Low $274.70
Volume 214,853
Shares Issued 43.56m
Market Cap $13,682m
Beta 0.01
RiskGrade 132

What The Brokers Say

Strong Buy 6
Buy 4
Neutral 5
Sell 0
Strong Sell 0
Total 15
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 22-Aug-2025

Time Volume / Share Price
12:32 100 @ $314.06
12:32 100 @ $314.10
12:30 100 @ $314.05
12:28 100 @ $313.95
12:28 100 @ $313.95

Top of Page